REGENXBIO Revenue 2014-2022 | RGNX

REGENXBIO revenue from 2014 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
REGENXBIO Annual Revenue
(Millions of US $)
2021 $470
2020 $155
2019 $35
2018 $219
2017 $10
2016 $5
2015 $8
2014 $6
2013 $6
REGENXBIO Quarterly Revenue
(Millions of US $)
2022-03-31 $22
2021-12-31 $399
2021-09-30 $31
2021-06-30 $22
2021-03-31 $19
2020-12-31 $21
2020-09-30 $99
2020-06-30 $17
2020-03-31 $18
2019-12-31 $12
2019-09-30 $15
2019-06-30 $8
2019-03-31 $1
2018-12-31 $41
2018-09-30 $5
2018-06-30 $40
2018-03-31 $132
2017-12-31 $2
2017-09-30 $1
2017-06-30 $7
2017-03-31 $0
2016-12-31 $2
2016-09-30 $0
2016-06-30 $2
2016-03-31 $0
2015-12-31 $4
2015-09-30 $1
2015-06-30 $1
2015-03-31 $1
2014-12-31
2014-09-30 $0
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.844B $0.470B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00